Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, updated its Ebola program, stating that it has started limited GMP manufacture of a new therapeutics targeting the Ebola-Guinea variant, which is the viral variant responsible for the Ebola outbreak currently prevalent in West Africa. Supply of that product will be available in early December for potential use by various collaborators.